{
    "organizations": [],
    "uuid": "749b05767f868db78c7c158edb8138c038a14ac6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ose-immunotherapeutics-to-resume-p/brief-ose-immunotherapeutics-to-resume-patient-accrual-in-u-s-for-phase-3-tedopi-clinical-trial-idUSASB0C7LL",
    "ord_in_thread": 0,
    "title": "BRIEF-Ose Immunotherapeutics To Resume Patient Accrual In U. S. For Phase 3 Tedopi Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 27, 2018 / 6:43 AM / Updated 2 minutes ago BRIEF-Ose Immunotherapeutics To Resume Patient Accrual In U. S. For Phase 3 Tedopi Clinical Trial Reuters Staff 1 Min Read Feb 27 (Reuters) - OSE IMMUNOTHERAPEUTICS SA: * OSE IMMUNOTHERAPEUTICS GRANTED APPROVAL TO RESUME PATIENT ACCRUAL IN U. S. FOR PHASE 3 TEDOPI CLINICAL TRIAL IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS FOLLOWING IMMUNE CHECKPOINT INHIBITOR TREATMENT * TRIAL WILL BE CONDUCTED IN TWO STEPS * PHASE 1: ENROLLMENT OF AROUND 100 PATIENTS AND PERFORMANCE ANALYSIS OF SURVIVAL DATA * PHASE 1: RESULTS EXPECTED IN APPROXIMATELY TWO YEARS * BASED ON PHASE 1 RESULTS WILL DETERMINE PHASE 2 * PRIMARY ENDPOINT OF TRIAL IS OVERALL SURVIVAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)",
    "published": "2018-02-27T08:43:00.000+02:00",
    "crawled": "2018-02-27T08:47:11.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "updated",
        "minute",
        "ago",
        "immunotherapeutics",
        "resume",
        "patient",
        "accrual",
        "phase",
        "tedopi",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "ose",
        "immunotherapeutics",
        "sa",
        "ose",
        "immunotherapeutics",
        "granted",
        "approval",
        "resume",
        "patient",
        "accrual",
        "phase",
        "tedopi",
        "clinical",
        "trial",
        "advanced",
        "cell",
        "lung",
        "cancer",
        "patient",
        "following",
        "immune",
        "checkpoint",
        "inhibitor",
        "treatment",
        "trial",
        "conducted",
        "two",
        "step",
        "phase",
        "enrollment",
        "around",
        "patient",
        "performance",
        "analysis",
        "survival",
        "data",
        "phase",
        "result",
        "expected",
        "approximately",
        "two",
        "year",
        "based",
        "phase",
        "result",
        "determine",
        "phase",
        "primary",
        "endpoint",
        "trial",
        "overall",
        "survival",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}